Abstract
Background Efficacy and effectiveness of vaccines against SARS-CoV-2 infection, severe disease and death have been widely assessed. However, the impact of vaccination against SARS-CoV-2 transmission is far less well-characterized, and has major implications for public health, because it informs the indirect effects of vaccination in addition to its direct effects. Analysing the effects of SARS-CoV-2 vaccination on transmission is challenging, because they must be considered in tandem with the time-varying reproduction number (Rt), while also accounting for regional variability, for example due to the presence of more transmissible variants.
Methods We fitted a Bayesian hierarchical model to previously obtained estimates of Rt to estimate the effectiveness of vaccination with one, two and three doses on SARS-CoV-2 transmission in the UK during 2021. Vaccine effectiveness is defined as the proportional reduction in the time-varying reproduction number Rt. The model accounts for transmission at national and Lower Tier Local Authority (LTLA)-level, and uses vaccination data provided by the UK Health Security Agency (UKHSA), detailing the LTLA-specific proportions of people who have received doses one, two and three. The model also incorporates data on the proportion of wild-type, Alpha and Delta SARS-CoV-2 variants over time in each LTLA, obtained from UKHSA and the COVID-19 Genomics UK (COG-UK) Consortium.
Results We find that vaccination had moderate-to-large effectiveness against transmission for dose 1 (39.30%, 95% CrI 26.64% - 48.07%), and for dose 3 (48.69%, 95% CrI 27.97% - 71.30%), but negligible effects on dose 2, likely attributable to the coincident importation and dominance of the Delta variant in the UK. Nationally, our model fitted the previously estimated values of time-series of Rt values well, largely reproducing the reproduction number averaged across LTLAs for each timepoint. This lends support to our hypothesis that the extent of vaccination (or lack thereof) was a major determinant of transmission intensity. Our model fits further reproduced well the reproduction numbers at regional level, although outliers were less well captured, implying some degree of variation that is not explained by our model.
Conclusions To our knowledge, our analysis is the first evidence of the effectiveness of SARS-CoV-2 vaccination against its transmission at population level. We find that vaccination is an effective tool for the control of SARS-CoV-2 transmission, in addition to its well-documented effects on disease burden and mortality. Our results allow future assessment of the impact of vaccination accounting for several circulating variants and sociodemographic factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ND, WRH, SB and DJL acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. SM acknowledges support from the National Research Foundation via The NRF Fellowship Class of 2023 Award (NRF-NRFF15-2023-0010). SB is funded by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Modelling and Health Economics, a partnership between UK Health Security Agency, Imperial College London and LSHTM (grant code NIHR200908). SB acknowledges: support from the Novo Nordisk Foundation via The Novo Nordisk Young Investigator Award (NNF20OC0059309); the Danish National Research Foundation (DNRF160) through the chair grant, and support from The Eric and Wendy Schmidt Fund For Strategic Innovation via the Schmidt Polymath Award (G-22-63345). DJL acknowledges funding from the Wellcome Trust for the Vaccine Impact Modelling Consortium (VIMC) Climate Change Research Programme (grant ID: 226727\_Z\_22\_Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All model code is available at https://github.com/NDerqui/Vaccine_Model.
